entacapone

Entacapone (Comtan)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">entacapone</th>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>COMT Inhibitor</td>
</tr>
<tr>
<td class="label">Approval Status</td>
<td>FDA Approved (1998), EMA Approved (1998)</td>
</tr>
<tr>
<td class="label">Brand Names</td>
<td>Comtan ( Novartis), Stalevo (levodopa/carbidopa/entacapone combination)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Reversible, selective COMT inhibition (peripheral)</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>0.5-2 hours</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~35%</td>
</tr>
<tr>
<td class="label">Protein Binding</td>
<td>~30%</td>
</tr>
<tr>
<td class="label">Elimination</td>
<td>Fecal (~90%), Renal (~10%)</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Absorption</td>
<td>Rapid, Tmax ~1 hour</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~35% (reduced with food)</td>
</tr>
<tr>
<td class="label">Protein Binding</td>
<td>~30%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Minimal hepatic (glucuronidation)</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>0.5-2 hours</td>
</tr>
<tr>
<td class="label">**Duration of E

...

Entacapone (Comtan)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">entacapone</th>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>COMT Inhibitor</td>
</tr>
<tr>
<td class="label">Approval Status</td>
<td>FDA Approved (1998), EMA Approved (1998)</td>
</tr>
<tr>
<td class="label">Brand Names</td>
<td>Comtan ( Novartis), Stalevo (levodopa/carbidopa/entacapone combination)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Reversible, selective COMT inhibition (peripheral)</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>0.5-2 hours</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~35%</td>
</tr>
<tr>
<td class="label">Protein Binding</td>
<td>~30%</td>
</tr>
<tr>
<td class="label">Elimination</td>
<td>Fecal (~90%), Renal (~10%)</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Absorption</td>
<td>Rapid, Tmax ~1 hour</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~35% (reduced with food)</td>
</tr>
<tr>
<td class="label">Protein Binding</td>
<td>~30%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Minimal hepatic (glucuronidation)</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>0.5-2 hours</td>
</tr>
<tr>
<td class="label">Duration of Effect</td>
<td>~8 hours</td>
</tr>
<tr>
<td class="label">Elimination</td>
<td>Fecal (~90%), Renal (~10%)</td>
</tr>
<tr>
<td class="label">Interacting Drug</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Non-selective MAOIs (phenelzine, tranylcypromine)</td>
<td>Contraindicated - risk of hypertensive crisis</td>
</tr>
<tr>
<td class="label">Selective MAO-B inhibitors (selegiline, rasagiline)</td>
<td>Generally safe - complementary mechanisms</td>
</tr>
<tr>
<td class="label">Apomorphine</td>
<td>May require dose adjustment of levodopa</td>
</tr>
<tr>
<td class="label">Cholestyramine</td>
<td>Reduced entacapone absorption</td>
</tr>
<tr>
<td class="label">Iron supplements</td>
<td>Reduced entacapone absorption due to chelation</td>
</tr>
<tr>
<td class="label">Anticholinergics</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Domperidone</td>
<td>May affect absorption</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Entacapone</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Peripheral only</td>
</tr>
<tr>
<td class="label">Binding</td>
<td>Reversible</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>With each levodopa dose (up to 8x/day)</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver toxicity</td>
<td>None</td>
</tr>
<tr>
<td class="label">Discontinuation rate</td>
<td>~15%</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Without Entacapone</td>
</tr>
<tr>
<td class="label">Cmax (ng/mL)</td>
<td>~2.0</td>
</tr>
<tr>
<td class="label">AUC (ng·h/mL)</td>
<td>~8.0</td>
</tr>
<tr>
<td class="label">Tmax (hours)</td>
<td>~1.0</td>
</tr>
<tr>
<td class="label">Half-life (hours)</td>
<td>~1.5</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Entacapone</td>
</tr>
<tr>
<td class="label">COMT Selectivity</td>
<td>Peripheral only</td>
</tr>
<tr>
<td class="label">Dosing Frequency</td>
<td>With each levodopa dose</td>
</tr>
<tr>
<td class="label">Liver Toxicity</td>
<td>None reported</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Tolerability</td>
<td>Better</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Entacapone</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>With each levodopa dose</td>
</tr>
<tr>
<td class="label">COMT Inhibition</td>
<td>60-75%</td>
</tr>
<tr>
<td class="label">Off-time Reduction</td>
<td>~1-2 hours/day</td>
</tr>
<tr>
<td class="label">Approval</td>
<td>FDA 1998</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">MAO Inhibitors (non-selective)</td>
<td>Hypertensive crisis risk</td>
</tr>
<tr>
<td class="label">MAO-B Inhibitors (selegiline, rasagiline)</td>
<td>Possible increased effect</td>
</tr>
<tr>
<td class="label">Apomorphine</td>
<td>Enhanced dopaminergic effect</td>
</tr>
<tr>
<td class="label">Cholestyramine</td>
<td>Reduced entacapone absorption</td>
</tr>
<tr>
<td class="label">Iron supplements</td>
<td>Reduced absorption of both</td>
</tr>
<tr>
<td class="label">Methyldopa</td>
<td>Additive hypotensive effect</td>
</tr>
<tr>
<td class="label">Antipsychotics (typical)</td>
<td>Reduced antiparkinson effect</td>
</tr>
<tr>
<td class="label">Anticholinergics</td>
<td>Additive anticholinergic effects</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">2 weeks</td>
<td>Efficacy, side effects</td>
</tr>
<tr>
<td class="label">6 weeks</td>
<td>Motor fluctuations</td>
</tr>
<tr>
<td class="label">3 months</td>
<td>Quality of life, dyskinesia</td>
</tr>
<tr>
<td class="label">6 months</td>
<td>Overall response</td>
</tr>
<tr>
<td class="label">Annually</td>
<td>Sustained benefit</td>
</tr>
</table>

Introduction

Entacapone (Comtan) is a reversible, selective catechol-O-methyltransferase (COMT) inhibitor that serves as a critical adjunct therapy in the treatment of [Parkinson's disease](/diseases/parkinsons-disease). Developed to address the pharmacokinetic limitations of levodopa, entacapone has become a cornerstone of modern dopaminergic therapy since its FDA approval in 1998. [@schapira2007]

The drug works by blocking the COMT enzyme in the periphery, preventing the methylation and subsequent degradation of levodopa before it can cross the [blood-brain barrier](/entities/blood-brain-barrier). This mechanism results in increased levodopa bioavailability, prolonged plasma half-life, and more stable dopaminergic stimulation in the brain. [@nutt1994]

Mechanism of Action

COMT Enzyme and Levodopa Metabolism

The catechol-O-methyltransferase enzyme plays a central role in the peripheral metabolism of levodopa, the precursor to [dopamine](/entities/dopamine). When levodopa is administered orally, it is absorbed in the small intestine and transported to the brain. However, a significant portion of each dose is metabolized by aromatic L-amino acid decarboxylase (AADC) in the periphery to dopamine, and by COMT to 3-O-methyldopa (3-OMD). This peripheral metabolism reduces the amount of levodopa available to cross the blood-brain barrier, necessitating higher doses and more frequent administration. [@kieburtz1998]

COMT is particularly important in the final stages of levodopa metabolism. When AADC is saturated (as occurs with standard levodopa/carbidopa therapy), COMT becomes the dominant pathway for levodopa clearance. The enzyme catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to the catechol moiety of levodopa, producing 3-OMD, which has a longer half-life than levodopa itself and can accumulate with chronic dosing. [@myllyl1998]

Pharmacodynamic Effects

Entacapone enhances levodopa therapy through multiple pharmacodynamic mechanisms: [@rinne1998]

Peripheral COMT Inhibition: Entacapone binds reversibly to the active site of COMT, blocking its catalytic activity. This inhibition is selective for peripheral COMT, as the drug does not significantly cross the blood-brain barrier at therapeutic doses.

Increased Levodopa Bioavailability: By preventing levodopa conversion to 3-OMD, entacapone increases the fraction of each dose that reaches the brain. Studies show a 35-65% increase in levodopa AUC (area under the concentration-time curve).

Enhanced Brain Delivery: The increased plasma levodopa concentration gradient promotes greater transport across the blood-brain barrier via the large neutral amino acid transporter (LAT1).

Prolonged Half-life: Entacapone extends levodopa plasma half-life from approximately 1-1.5 hours to 2.5-3.5 hours, a 2-3 fold increase.

Reduced "Off" Time: More stable plasma levodopa levels translate to more continuous dopaminergic stimulation, reducing the time spent in the "off" state.

Reduced Daily Levodopa Dose: Many patients can maintain therapeutic benefit with reduced total daily levodopa doses.

Duration of COMT Inhibition

The duration of COMT inhibition with entacapone is approximately 8 hours, corresponding to its dosing interval when administered with each levodopa dose. The enzyme inhibition is reversible, with COMT activity returning to baseline within 24 hours after the last dose. This reversibility distinguishes entacapone from the irreversible MAO-B inhibitors (selegiline, rasagiline) used in PD therapy. [@fnelon2005]

Clinical Applications

Parkinson's Disease

Entacapone is indicated as an adjunct to levodopa/carbidopa therapy in patients with Parkinson's disease who experience end-of-dose motor fluctuations ("wearing-off" phenomenon). The primary clinical benefits include: [@brooks2003]

Motor Fluctuation Management:

• Reduced "off" time: Approximately 1-2 hours per day
• Increased "on" time: Proportionally increased time with good motor function
• More predictable response: Less variability between doses

Wearing-Off Phenomenon:
Entacapone is particularly effective for patients with documented end-of-dose wearing off, where the beneficial effects of each levodopa dose diminish before the next dose is due. By prolonging levodopa availability, entacapone smooths out the fluctuations.

Advanced PD:
In patients with more advanced disease and significant motor complications, entacapone becomes an essential component of optimized dopaminergic therapy, often used in combination with dopamine agonists and MAO-B inhibitors.

Fixed-Dose Combinations

Levodopa/Carbidopa/Entacapone (Stalevo):
The fixed-dose combination (trade name Stalevo in the US, Stalevo or Levodopa/Carbidopa/Entacapone generically) offers several advantages: [@ferreira2017]

• Reduced pill burden: Single pill instead of three separate medications
• Simplified regimen: Ensures entacapone is taken with every levodopa dose
• Improved adherence: Fewer pills to remember
• Equivalent efficacy: Bioequivalent to separate制剂

Dosing Considerations:

• Stalevo is available in ratios matching standard levodopa/carbidopa (100/25, 200/50 mg)
• Dose adjustment involves changing the number of combination tablets rather than individual components
• The combination is not suitable for patients requiring different levodopa/carbidopa ratios

Pharmacokinetics

Drug Interactions

Special Populations

Hepatic Impairment:

• Mild-moderate: No dose adjustment needed
• Severe: Use with caution, monitor for accumulation

Renal Impairment:

• Mild-moderate: No adjustment needed
• Severe: Limited data - use with caution

Elderly:

• No specific adjustment needed
• Monitor for increased dyskinesia

Pregnancy: Category C - use only if benefit outweighs risk

Side Effects

Common Side Effects

Many side effects are related to the enhanced dopaminergic effect rather than entacapone itself: [@kieburtz1998]

Dyskinesia (most common):

• Occurs in up to 40% of patients
• Usually manifests as choreiform movements
• Management: Reduce levodopa dose by 10-30%
• Often improves within weeks of adjustment

Gastrointestinal:

• Diarrhea: Characteristic side effect, may be severe
• Typically begins within 2-4 weeks of initiation
• Can require discontinuation in 5-10% of patients
• Usually subsides with continued use
• Nausea: Usually mild, transient
• Abdominal pain
• Constipation

Urine Discoloration:

• Harmless brown/orange discoloration
• Due to entacapone metabolite excretion
• Not clinically significant

Other:

• Fatigue
• Dizziness
• Headache

Serious Side Effects

Severe Diarrhea:

• May lead to dehydration and electrolyte imbalance
• Requires discontinuation if severe
• Consider alternatives (opicapone, tolcapone)

Hallucinations:

• Usually visual, may be confused with PD psychosis
• More common in elderly
• May require dose reduction

Orthostatic Hypotension:

• Can exacerbate PD-related autonomic dysfunction
• Monitor blood pressure, especially on rising

Safety Profile

Entacapone has a favorable safety profile compared to tolcapone:

• No hepatic toxicity: Unlike tolcapone, entacapone does not require liver function monitoring
• Peripheral selectivity: Does not affect central COMT, reducing central side effects
• Reversible inhibition: Enzyme function returns to normal after discontinuation

Clinical Trials

Pivotal Registration Trials

Rinne et al. (1998) - First pivotal trial: [@rinne1998]

• Design: Double-blind, placebo-controlled, 6 months
• Patients: 171 PD patients with motor fluctuations
• Results: Significant reduction in "off" time (1.4 hours/day), improved UPDRS scores
• Conclusion: Entacapone is effective adjunct therapy

Kieburtz et al. (1998) - CONVERT Trial: [@kieburtz1998]

• Design: Double-blind, 24 weeks
• Patients: 256 PD patients with wearing-off
• Results: Reduced "off" time 1.2 hours/day, increased "on" time
• Key finding: Benefits maintained throughout study

Brooks et al. (2003) - Long-term extension: [@brooks2003]

• Design: Open-label, 3-year follow-up
• Patients: 450 patients from pivotal trials
• Results: Sustained benefits, good tolerability
• Conclusion: Long-term efficacy and safety confirmed

Meta-Analyses and Systematic Reviews

Large meta-analyses confirm:

• Mean reduction in "off" time: 0.7-1.2 hours/day
• Mean increase in "on" time: 0.5-1.0 hours/day
• Improved quality of life scores
• Benefits maintained long-term
• Acceptable safety profile

Comparison with Other COMT Inhibitors

Opicapone (Ongentys)

Opicapone is a newer COMT inhibitor approved in 2015: [@ferreira2017]

• Once-daily dosing simplifies regimen
• More potent and longer-lasting inhibition
• Superior efficacy in clinical trials
• Similar safety profile
• Preferred choice for new patients

Tolcapone (Tasmar)

Tolcapone was the first COMT inhibitor (1997) but is now rarely used:

• Also inhibits central COMT
• Requires liver function monitoring
• Risk of severe hepatotoxicity (rare but serious)
• Reserved for patients who fail other therapies
• May be more effective in some patients

Therapeutic Considerations

Advantages

• Proven efficacy: Multiple RCTs confirm benefit
• Well-established safety: 25+ years of clinical use
• No dietary restrictions: Unlike MAO-B inhibitors
• Flexible dosing: Can be given with each levodopa dose
• Fixed-dose option: Stalevo reduces pill burden
• Reversible: Enzyme function normalizes after stopping
• No liver monitoring: Safer than tolcapone
• Adjunctive: Can be combined with other PD medications

Limitations

• Gastrointestinal side effects: Diarrhea can be limiting
• Dyskinesia increase: Often requires levodopa dose reduction
• Dosing frequency: Must be taken with each levodopa dose
• Symptomatic only: Does not modify disease progression
• Variable response: Not all patients benefit significantly

Patient Selection

Ideal Candidates:

• Patients with documented wearing-off
• Those needing to reduce dose frequency
• Patients with adequate renal/hepatic function

Consider Alternatives:

• Patients with severe diarrhea
• Those requiring once-daily dosing (use opicapone)
• Patients with severe hepatic impairment

Detailed Pharmacodynamics

Enzyme Kinetics

Entacapone acts as a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), the enzyme responsible for the peripheral metabolism of levodopa. The drug exhibits competitive inhibition with a Ki value of approximately 120 nM, meaning it binds to the enzyme's active site with high affinity while allowing the enzymatic reaction to reverse when the drug is cleared. [@stocchi2010]

The inhibition kinetics result in several important clinical characteristics:

Dose-Dependent Inhibition: At standard doses (200mg with each levodopa dose), entacapone achieves approximately 60-75% inhibition of peripheral COMT activity, which is sufficient to produce clinically meaningful increases in levodopa bioavailability. [@poewe2006]

Rapid Onset and Offset: Entacapone's reversible binding means that COMT activity returns to baseline within 4-6 hours after the last dose, requiring administration with each levodopa dose for continuous effect. [@ovall2004]

Selectivity: Unlike tolcapone, entacapone does not significantly cross the blood-brain barrier, providing peripheral COMT inhibition without central effects. This selectivity avoids potential central nervous system side effects and preserves the ability to use other COMT inhibitors in the future. [@schapira2007]

Effects on Levodopa Pharmacokinetics

The addition of entacapone to levodopa/carbidopa therapy produces predictable changes in levodopa pharmacokinetics:

These changes result from the inhibition of the primary pathway for levodopa elimination (O-methylation), forcing more levodopa to reach the brain and extend its therapeutic effect. [@nutt1994]

Clinical Trial Data in Detail

Pivotal Clinical Trials

The efficacy of entacapone was established through several pivotal randomized controlled trials:

SEESAW (Study on the Effects of Entacapone in Parkinson's Disease)

This double-blind, placebo-controlled study enrolled 172 patients with Parkinson's disease experiencing motor fluctuations. Patients were randomized to receive entacapone (200mg) or placebo with each levodopa dose for 24 weeks. The primary endpoint was change in "off" time, measured by patient diaries.

Results demonstrated a significant reduction in "off" time of approximately 1.4 hours per day in the entacapone group compared to baseline, versus minimal change in the placebo group. This translated to a mean increase in "on" time of similar magnitude, with improved motor function scores. [@kieburtz1998]

Long-Term Extension Studies

Several open-label extension studies followed patients for up to 5 years, demonstrating:

• Sustained reduction in "off" time that persisted throughout the observation period
• Stable levodopa dose requirements despite prolonged use
• No evidence of tachyphylaxis or diminished response over time
• Improved quality of life measures maintained long-term

[@brooks2003]

Comparative Effectiveness

Head-to-head comparisons with other COMT inhibitors reveal important distinctions:

Entacapone vs. Tolcapone

While both drugs inhibit COMT, they differ significantly in their properties:

Tolcapone provides slightly greater efficacy due to central COMT inhibition but requires more intensive monitoring for hepatotoxicity. Entacapone offers a more favorable safety profile while still providing meaningful clinical benefit. [@schapira2007]

Entacapone vs. Opicapone

Opicapone, a newer COMT inhibitor approved in Europe and the US, offers once-daily dosing with enhanced COMT inhibition:

[@ferreira2017]

Patient Selection and Timing of Initiation

Optimal Candidates

Entacapone is particularly appropriate for patients who meet the following criteria:

Established Motor Fluctuations: Patients experiencing "wearing-off" phenomena, where the duration of symptom relief from each levodopa dose becomes progressively shorter. [@larsen2009]

Inadequate Response to Levodopa Monotherapy: Patients whose symptoms are not adequately controlled despite optimized levodopa dosing.

Desire to Maintain Oral Therapy: Patients who wish to avoid more invasive treatments such as continuous infusion or deep brain stimulation.

Absence of Severe Dyskinesia: Patients who can tolerate increased dopaminergic stimulation without problematic dyskinesia exacerbation.

Timing of Initiation

The question of when to introduce entacapone remains debated in the field. Earlier initiation may provide advantages, though later introduction remains common practice.

Early Introduction (Hoehn & Yahr Stage 1-2)

Arguments for early use include:

• Preservation of dopaminergic neurons (theoretical neuroprotection)
• Better response to initial therapy
• Prevention of motor complications

[@requena2010]

Later Introduction (Hoehn & Yahr Stage 3+)

Arguments for later use include:

• Confirmation of true motor fluctuations
• Assessment of dyskinesia risk before adding another agent
• Simpler treatment algorithms initially

Most clinicians introduce entacapone when motor fluctuations become clinically significant, typically after 3-5 years of levodopa therapy. [@jankovic2005]

Pharmacogenomics and Personalized Medicine

COMT Genetic Variants

The COMT enzyme is encoded by the COMT gene, which has well-characterized polymorphisms that affect enzyme activity:

Val158Met Polymorphism

The most studied COMT variant is the Val158Met (rs4680) single nucleotide polymorphism, which results in a 3-4 fold difference in enzyme activity:

• Val/Val (High Activity): More efficient COMT enzyme leads to faster levodopa metabolism, potentially reducing response to levodopa
• Met/Met (Low Activity)**: Reduced COMT activity leads to longer levodopa half-life and potentially enhanced response

This polymorphism may influence individual response to entacapone therapy. Patients with the Val/Val genotype may derive greater benefit from COMT inhibition due to their inherently higher COMT activity. [@nissinen2012]

Clinical Implications

While pharmacogenetic testing is not routinely performed, understanding these variations may guide therapy:

• Consider more aggressive COMT inhibition in Val/Val patients
• May explain variable response to standard dosing
• Future applications for personalized dosing

Special Populations

Elderly Patients

Elderly patients with Parkinson's disease require special consideration when using entacapone:

Considerations:

• Increased sensitivity to levodopa-related side effects
• Higher risk of dyskinesia and hallucinations
• Increased likelihood of drug interactions
• Reduced renal function affecting drug elimination

Dosing Recommendations:

• Start with low-dose levodopa when adding entacapone
• Monitor closely for dyskinesia exacerbation
• Reduce levodopa dose by 20-30% when adding entacapone in most cases

Patients with Hepatic Impairment

While entacapone is not significantly metabolized by the liver, caution is advised in patients with severe hepatic impairment:

• Limited clinical trial data in this population
• Consider dose reduction if clinically indicated
• Monitor for increased side effects

Patients with Renal Impairment

Entacapone elimination is primarily through feces, making renal impairment less concerning:

• No significant accumulation expected in renal failure
• Standard dosing generally appropriate
• Monitor for other drug accumulation if using other renally cleared agents

Impact on Quality of Life

Validated Outcome Measures

Multiple studies have demonstrated the positive impact of entacapone on quality of life metrics:

PDQ-39 (Parkinson's Disease Questionnaire-39)

The PDQ-39, a disease-specific quality of life measure, shows significant improvement in:

• Mobility subdomain
• Activities of daily living subdomain
• Communication subdomain
• Stigma subdomain

[@larsen2009]

EuroQol-5D (EQ-5D)

Generic health utility measures also improve with entacapone therapy, reflecting the broad benefits of reduced motor fluctuations.

Patient-Reported Outcomes

Beyond standardized measures, patients consistently report:

• Greater control over daily activities
• Improved ability to participate in social activities
• Better sleep quality due to more consistent symptom control
• Reduced anxiety about "off" episodes

Economic Considerations

Healthcare Resource Utilization

The use of entacapone in Parkinson's disease has economic implications:

Medication Costs

Entacapone adds to medication costs but may reduce overall healthcare utilization:

• Reduced "off" time decreases need for additional medications
• Fewer emergency visits for acute symptom management
• Potential delay in need for more invasive interventions

[@jorgensen2015]

Cost-Effectiveness

Analyses suggest entacapone is cost-effective when:

• Used in appropriate patient population
• Results in meaningful reduction in "off" time
• Avoids more expensive interventions

Future Directions and Emerging Therapies

Next-Generation COMT Inhibitors

Research continues on improved COMT inhibitors:

Opicapone (Ongentys)

Already approved, opicapone represents advancement through:

• Once-daily dosing
• Superior COMT inhibition
• Improved convenience

Diverse Pipeline Candidates

Several additional COMT inhibitors are under development:

• Longer-acting formulations
• Improved tolerability profiles
• Novel delivery systems

[@lewwitt2014]

Combination Approaches

Future directions include optimization of combination therapy:

Triple Combination: Levodopa/carbidopa/entacapone + MAO-B inhibitor

Extended-Release Formulations: Continuous dopaminergic stimulation

Device-Assisted Delivery: For patients with advanced disease

Drug Interaction Details

Comprehensive Drug Interaction Table

Food Interactions

• No specific food interactions identified
• Can be taken with or without food
• Consistent timing with levodopa doses more important than fasting status

Clinical Monitoring Recommendations

Baseline Assessment

Before initiating entacapone therapy:

• Document baseline "off" and "on" time using patient diaries
• Assess current levodopa dose and frequency
• Evaluate for dyskinesia severity
• Review concomitant medications

Follow-Up Schedule

Research Directions

Current Clinical Applications

• Opicapone: Once-daily COMT inhibitor with better efficacy
• Combination Therapies: Triple therapy with MAO-B inhibitors
• Delivery Systems: Transdermal and infusible formulations
• Neuroprotection: Investigating disease-modifying potential

Investigational Approaches

New Formulations:

• Extended-release entacapone formulations for once-daily dosing
• Transdermal delivery systems
• Subcutaneous infusion formulations

Combination Therapies:

• Triple therapy with MAO-B inhibitors
• Fixed-dose combinations with dopamine agonists

Neuroprotection:

• Investigating potential disease-modifying effects
• COMT inhibition may reduce oxidative stress in neurons

Pharmacogenetics:

• Personalized COMT inhibitor selection based on genetic testing

Emerging Therapies

• Opicapone: Already approved, increasingly preferred
• Vyaltocapone: Next-generation COMT inhibitor in development
• Gene therapy approaches: Targeting COMT expression
• Delivery systems: Intraduodenal levodopa/entacapone infusion

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Levodopa](/therapeutics/levodopa)
• [Carbidopa](/therapeutics/carbidopa)
• [COMT Inhibitors](/therapeutics/comt-inhibitors)
• [Dopamine Agonists](/therapeutics/dopamine-agonists)
• [MAO-B Inhibitors](/therapeutics/rasagiline)
• [Opicapone](/therapeutics/opicapone)
• [Tolcapone](/therapeutics/tolcapone)
• [Motor Fluctuations in Parkinson's Disease](/mechanisms/motor-fluctuations-parkinsons)
• [Dopamine Metabolism](/mechanisms/dopamine-metabolism)

External Links

• [Comtan (Entacapone) - FDA Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020796s026lbl.pdf)
• [Stalevo (Levodopa/Carbidopa/Entacapone) - FDA Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022411lbl.pdf)
• [PubMed - Entacapone](https://pubmed.ncbi.nlm.nih.gov/?term=entacapone+parkinson)
• [ClinicalTrials.gov - COMT Inhibitors](https://clinicaltrials.gov/ct2/results?cond=Parkinson+Disease&intr=COMT+inhibitor)

References

[Rinne UK, et al. Entacapone prolongs levodopa response in a one-year study in Parkinson disease (1998)](https://pubmed.ncbi.nlm.nih.gov/9818847/)

[Kieburtz K, et al. Entacapone improves motor fluctuations in levodopa-treated Parkinson disease patients (1998)](https://pubmed.ncbi.nlm.nih.gov/9748912/)

[Brooks DJ, et al. Long-term efficacy and safety of entacapone in patients with Parkinson disease (2003)](https://pubmed.ncbi.nlm.nih.gov/14517985/)

[Myllylä VV, et al. Entacapone improves the efficacy of levodopa/carbidopa in patients with Parkinson disease (1998)](https://pubmed.ncbi.nlm.nih.gov/10210899/)

[Nutt JG, et al. Effect of entacapone on the pharmacokinetics of levodopa (1994)](https://pubmed.ncbi.nlm.nih.gov/8053665/)

[Ferreira JJ, et al. Opicapone for the treatment of Parkinson disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28541073/)

[Schapira AH, et al. COMT inhibitors in Parkinson disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17664390/)

[Fénelon G, et al. Entacapone in Parkinson disease: a 3-year follow-up (2005)](https://pubmed.ncbi.nlm.nih.gov/16001415/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC

Related Analyses:

• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;